ArticleBlood cancer journal2025

IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial.

Sheng-Li Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.